DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Jetstar to Charge for Overhead Cabin Bags From February 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Salt Lake City, March 22, 2018 -- SelectHealth has signed a value-based contract with Novo Nordisk, a leader in diabetes care, to measure outcomes among patients with type 2 diabetes using Victoza® (liraglutide). Victoza may improve blood sugar in adults with type 2 diabetes when used in conjunction with diet and exercise.
|
|||
Both SelectHealth and Novo Nordisk will track metrics built into the contract designed to measure and understand how members use Victoza and how it supports their diabetes and overall healthcare goals.
Eric Cannon, SelectHealth Pharmacy Benefit Services AVP, said “Diabetes is a significant driver of cost. We are excited to enter into an agreement that is focused on improving clinical outcomes and providing value to our members. SelectHealth and Intermountain Healthcare will continue to explore value-based opportunities that improve health and value for our members.”
“Due to the costs associated with unmanaged diabetes and its increasing prevalence in the US, value-based contracting can help us learn more about how our medicines can improve patients’ lives,” said Todd Hobbs, MD, chief medical officer, Novo Nordisk Inc. “We stand behind the clinical value of our medicines, and consider this contract an exciting opportunity to not only showcase this efficacy, but also to improve access for patients.”
###
SelectHealth is a not-for-profit health plan that serves more than 850,000 members in Utah and Idaho. Through a shared mission with Intermountain Healthcare of Helping People Live the Healthiest Lives Possible®, we are committed to assuring access to high-value care, providing superior service, and supporting the health of our members and the communities we serve.
In addition to medical plans, SelectHealth offers dental, vision, pharmacy benefit management, and life and disability coverage to its members. SelectHealth plans are available for Medicare Advantage and Medicaid enrollees, and we’re also a carrier for the Children’s Health Insurance Plan (CHIP) and the Federal Employee Health Benefits (FEHB) Plan.
Year-after-year, SelectHealth is rated as Utah’s top HMO plan by state and national organizations, receiving top scores in both member satisfaction and clinical performance. For details, visit selecthealth.org.
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/bc6f12a7-a775-43ce-8a3f-221a70b893c1
SelectHealth Media SelectHealth 801-442-7962 [email protected]
